Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine ApproachPharmacological reviews, 2018-04, Vol.70 (2), p.348-383 [Peer Reviewed Journal]Copyright © 2018 by The Author(s). ;info:eu-repo/semantics/openAccess © 2018 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/). http://creativecommons.org/licenses/by/4.0/ ;ISSN: 0031-6997 ;EISSN: 1521-0081 ;DOI: 10.1124/pr.117.014753 ;PMID: 29507103Full text available |
|
2 |
Material Type: Article
|
On the alert for cytokine storm: Immunopathology in COVID‐19Arthritis & Rheumatology, 2020-07 [Peer Reviewed Journal]2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com ;DOI: 10.1002/art.41285Digital Resources/Online E-Resources |
|
3 |
Material Type: Article
|
Targeting inflammation in atherosclerosis - from experimental insights to the clinicNature reviews. Drug discovery, 2021-08, Vol.20 (8), p.589-610 [Peer Reviewed Journal]2021. Springer Nature Limited. ;COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1776 ;ISSN: 1474-1784 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-021-00198-1 ;PMID: 33976384Full text available |
|
4 |
Material Type: Article
|
Can Activation of NRF2 Be a Strategy against COVID-19?Trends in Pharmacological Sciences, 2020-09 [Peer Reviewed Journal]2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;DOI: 10.1016/j.tips.2020.07.003Digital Resources/Online E-Resources |
|
5 |
Material Type: Article
|
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from ChinaClinical Immunology, 2020-05, Vol.214 [Peer Reviewed Journal]2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;DOI: 10.1016/j.clim.2020.108393Digital Resources/Online E-Resources |
|
6 |
Material Type: Article
|
Colchicine in Patients with Chronic Coronary DiseaseThe New England journal of medicine, 2020-11, Vol.383 (19), p.1838-1847 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2021372 ;PMID: 32865380Full text available |
|
7 |
Material Type: Article
|
Inflammation in Heart Failure: JACC State-of-the-Art ReviewJournal of the American College of Cardiology, 2020-03, Vol.75 (11), p.1324-1340 [Peer Reviewed Journal]Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2020.01.014 ;PMID: 32192660Full text available |
|
8 |
Material Type: Article
|
Current Mechanistic Concepts in Ischemia and Reperfusion InjuryCellular physiology and biochemistry, 2018-05, Vol.46 (4), p.1650-1667 [Peer Reviewed Journal]2018 The Author(s). Published by S. Karger AG, Basel ;2018 The Author(s). Published by S. Karger AG, Basel. ;ISSN: 1015-8987 ;EISSN: 1421-9778 ;DOI: 10.1159/000489241 ;PMID: 29694958Full text available |
|
9 |
Material Type: Article
|
Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic ConsiderationsSchizophrenia bulletin, 2018-08, Vol.44 (5), p.973-982 [Peer Reviewed Journal]The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;ISSN: 0586-7614 ;EISSN: 1745-1701 ;DOI: 10.1093/schbul/sby024 ;PMID: 29648618Full text available |
|
10 |
Material Type: Article
|
Resolution of inflammation: a new therapeutic frontierNature reviews. Drug discovery, 2016-08, Vol.15 (8), p.551-567 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Aug 2016 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2016.39 ;PMID: 27020098Full text available |
|
11 |
Material Type: Article
|
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19Cell host & microbe, 2021-07, Vol.29 (7), p.1052-1062 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 1931-3128 ;EISSN: 1934-6069 ;DOI: 10.1016/j.chom.2021.05.004 ;PMID: 34022154Full text available |
|
12 |
Material Type: Article
|
Severe Covid-19New England Journal of Medicine, 2020-12, Vol.383 (25), p.2451-2460 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMcp2009575 ;PMID: 32412710Digital Resources/Online E-Resources |
|
13 |
Material Type: Article
|
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenJournal of the European Academy of Dermatology and Venereology, 2020-12, Vol.34 (12), p.2717 [Peer Reviewed Journal]ISSN: 0926-9959 ;EISSN: 1468-3083 ;DOI: 10.1111/jdv.16892Digital Resources/Online E-Resources |
|
14 |
Material Type: Article
|
Chronic Heart Failure and Inflammation: What Do We Really Know?Circulation research, 2016-06, Vol.119 (1), p.159-176 [Peer Reviewed Journal]2016 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.116.308030 ;PMID: 27340274Full text available |
|
15 |
Material Type: Article
|
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical TrialJAMA, 2020-10 [Peer Reviewed Journal]2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://jamanetwork.com/journals/jama/pages/coronavirus-alert . ;DOI: 10.1001/jama.2020.17021Digital Resources/Online E-Resources |
|
16 |
Material Type: Article
|
Targeting immunometabolism as an anti-inflammatory strategyCell research, 2020-04, Vol.30 (4), p.300-314 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1001-0602 ;EISSN: 1748-7838 ;DOI: 10.1038/s41422-020-0291-z ;PMID: 32132672Full text available |
|
17 |
Material Type: Article
|
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?Clinical and Experimental Rheumatology, 2020-03, Vol.38 (2), p.337-342 [Peer Reviewed Journal]ISSN: 0392-856X ;EISSN: 1593-098X ;DOI: 10.55563/CLINEXPRHEUMATOL/XCDARY ;PMID: 32202240Full text available |
|
18 |
Material Type: Article
|
Therapeutic developments for Duchenne muscular dystrophyNature reviews. Neurology, 2019-07, Vol.15 (7), p.373-386 [Peer Reviewed Journal]COPYRIGHT 2019 Nature Publishing Group ;Springer Nature Limited 2019. ;ISSN: 1759-4758 ;EISSN: 1759-4766 ;DOI: 10.1038/s41582-019-0203-3 ;PMID: 31147635Full text available |
|
19 |
Material Type: Article
|
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trialBMJ (Online), 2021-01, Vol.372, p.n84 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.n84 ;PMID: 33472855Full text available |
|
20 |
Material Type: Article
|
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular DiseaseCirculation research, 2020-04, Vol.126 (9), p.1260-1280 [Peer Reviewed Journal]2020 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.120.315937 ;PMID: 32324502Full text available |